20-F: Alterity Therapeutics Reports Annual Results, Cites Going Concern Uncertainty

Alterity Therapeutics' annual report reveals ongoing operating losses and a need for additional funding, raising substantial doubt about its ability to continue as a going concern.

Summary

• Alterity Therapeutics Limited's annual report for the fiscal year ended June 30, 2024, highlights the company's focus on developing therapeutic drugs for neurodegenerative diseases.
• The company's lead drug candidate, ATH434, is in Phase 2 clinical trials for Multiple System Atrophy (MSA) and is also being investigated for Parkinson's disease.
• The report acknowledges significant operating losses, with a net loss of A$19,123,464 for the year ended June 30, 2024, and an accumulated deficit of A$214,161,131.
• Management expresses substantial doubt about the company's ability to continue as a going concern due to the need for additional funding to advance research and development programs.
• The company intends to seek additional funding through public or private financings, licensing agreements, or strategic alliances.
• The report also details various risks associated with the company's business, including uncertainties in research, clinical trials, regulatory approvals, intellectual property protection, and market acceptance.
• The company is subject to Australian takeover laws, which may discourage takeover offers or the acquisition of large numbers of ordinary shares.
• The company is also subject to the U.S. Foreign Corrupt Practices Act and could be adversely affected by violations of this act.
• The company is also subject to stringent and evolving U.S. and foreign laws, regulations, rules, contractual obligations, industry standards, policies and other obligations related to data privacy and security.
• The company is also subject to the Inflation Reduction Act (IRA) of 2022 which will likely result in reductions in Medicare payments and other health care expenditures that may impact the product candidates in the future.

Sentiment

Score: 4

Explanation: The document presents a mixed sentiment. While there is progress in clinical trials and Orphan Drug designation, the financial situation raises concerns about the company's future viability. The risks outlined further dampen the overall sentiment.

Positives

• ATH434 has shown promise in preclinical studies, reducing -synuclein pathology and preserving nerve cells.
• ATH434 has successfully completed Phase 1 clinical studies demonstrating the agent is well tolerated, orally bioavailable, and achieved brain levels comparable to efficacious levels in animal models of MSA.
• ATH434 has been granted Orphan Drug designation for the treatment of MSA by the U.S. FDA and the European Commission, providing market exclusivity and development incentives.
• The company has a robust discovery platform with over 1000 validated compounds in its chemical library.
• The company has a sub-licensing agreement for PBT2 to advance compounds for the treatment of Alzheimers and related diseases.

Negatives

• The company has a history of operating losses and a significant accumulated deficit.
• Management expresses substantial doubt about the company's ability to continue as a going concern.
• The company is dependent on securing additional funding, which may not be available or may dilute existing shareholders.
• Clinical trials are expensive, time-consuming, and their outcome is uncertain.
• The company has limited large-scale manufacturing experience with its product candidates.
• Acceptance of the company's products in the marketplace is uncertain.
• The company's stock price may be volatile and the trading market for its securities is limited.

Risks

• The company's research programs may not lead to desired results.
• Clinical trials may not demonstrate adequate safety or sufficient effectiveness.
• The company may experience delays in clinical trials.
• The company may not be able to complete the development of its product candidates.
• The company may need to prioritize the development of its most promising candidates at the expense of others.
• The company may be exposed to product liability claims.
• Breaches of network or information technology security could have an adverse effect on the company's business.
• The company's success depends on its ability to protect its intellectual property.
• The company may fail to maintain effective internal control over financial reporting.
• The company may be classified as a passive foreign investment company (PFIC), which could have adverse tax consequences for U.S. investors.
• The company's location in Australia presents challenges in enforcing judgments in the United States and complying with U.S. securities laws.
• Australian takeovers laws may discourage takeover offers.
• The company is currently operating in a period of economic uncertainty and capital markets disruption, which has been significantly impacted by geopolitical instability due to the ongoing military conflicts such as in the Middle East and between Russia and Ukraine.

Future Outlook

The company expects to continue incurring losses and will need to raise additional capital to continue its research and development programs.

Industry Context

The pharmaceutical industry is highly competitive, with numerous major pharmaceutical companies, biotechnology firms, universities, and research institutions developing technologies and products for the treatment of diseases that Alterity has targeted.

Comparison to Industry Standards

• There are currently no approved drugs for the treatment of Multiple System Atrophy (MSA).
• If Alterity is able to successfully develop ATH434 and gain approval for the treatment of MSA, it may compete with drug candidates in development such as Lu AF82422 (H. Lundbeck A/S), TAK-341/MEDI341 (Takeda/AstraZeneca), Ono-2808 (Ono Pharmaceuticals), AAV-GDNF (AskBio), and TEV-56286(formerly/Anle138b) (Teva Pharmaceuticals).

Related Party Transactions

• Includes $169,000 corporate advisory fees paid to an associate entity of Mr. Geoffrey Kempler for business advisory services including investor relations, marketing and business development.

Stakeholder Impact

• Shareholders face the risk of dilution from additional financings and potential loss of investment if the company cannot continue as a going concern.
• Employees face uncertainty regarding job security due to the company's financial situation.
• Patients with MSA and Parkinson's disease may benefit from the development of new therapies, but the success of these therapies is uncertain.
• Collaborators and partners face the risk of delays or termination of research and development programs if the company cannot secure additional funding.

Next Steps

• The ATH434-201 trial is expected to be completed in November 2024 with topline data expected in January 2025.
• Topline data from the ATH434-202 trial is expected in the first half of 2025.
• The company intends to convert a provisional patent application in the USA to a nonprovisional in September 2024.
• The company intends to continue to seek additional funding through public or private financings, licensing agreements, or strategic alliances.

Key Dates

Keywords

ATH434, Multiple System Atrophy, Parkinson's disease, clinical trials, neurodegenerative diseases, Alterity Therapeutics, financial results, Orphan Drug designation, research and development, going concern, funding, intellectual property, ASX, NASDAQ